What is PCOS renamed to PMOS?

PCOS renamed to PMOS

A global medical consortium of doctors and researchers has announced a new name for polycystic ovary syndrome. PCOS will now be called PMOS, short for polyendocrine metabolic ovarian syndrome.

The change matters because the original label—“polycystic ovary syndrome”—often led people to focus narrowly on the appearance of ovaries, particularly cyst-like structures. The updated wording instead points to a broader condition involving hormonal (polyendocrine) and metabolic factors (including insulin-related and weight/metabolism patterns), which can influence symptoms and long-term health risks.

For patients, a new acronym can affect how symptoms are discussed and how clinicians explain the condition. It also matters for education and research: the terminology used in medical training, patient materials, and studies can shape what outcomes are measured and how care guidelines are developed.

For the broader public, the renaming reflects a wider shift in medicine—reframing diagnoses to better match what is known about mechanisms rather than relying on older, partly descriptive names. The updated term is designed to better align with the hormonal and metabolic character of the syndrome, not just ovarian imaging findings.

No additional details were provided in the available story about when the new name will be adopted in every clinical system or how quickly health organizations will update textbooks, coding, or patient paperwork.